Pembrolizumab Improves Outcomes in Early-Stage and Locally Advanced or Metastatic Triple-Negative Breast Cancer
Author:
- Anne JacobsonAJAnne Jacobson
Open Access
- 1 March 2022
- journal article
- editorial
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 27 (Supplement) , S17-S18
Abstract
Pembrolizumab targets the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) signaling pathway across a range of tumor types with varying degrees of PD-L1 expression. The phase III KEYNOTE-522 and KEYNOTE-355 trials evaluated the addition of pembrolizumab to standard chemotherapy in patients with early-stage and locally advanced or metastatic triple-negative breast cancer (TNBC), respectively 1, 2. Updated findings provide insights on the optimal role of pembrolizumab across TNBC treatment settings.Keywords
This publication has 2 references indexed in Scilit:
- Abstract GS1-02: Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancerCancer Research, 2022
- Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analysesCancer Research, 2022